Quarterly report (Form 10-Q)
Caris Life Sciences 10-Q for Quarter ended Sep 30, 2026
Filing excerpt
Revenue from clinical cases for patients covered by Medicare represented approximately 36.9% and 39.4% of our molecular profiling services revenue for the three months ended September 30, 2026 and 2025, respectively.